Findings show no increased bleeding risk in hospitalized IBD patients receiving VTE prophylaxis, suggesting safety for this group.
Our findings suggest that there is no increased risk of bleeding in patients admitted with IBD exacerbation receiving pharmacological VTE prophylaxis during the admission period. However, prospective data, including high-risk patients (e.g., patients with cancer and pregnant women), is warranted.
No takes yet. Share an insight, caveat, or question.
Alrashed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: